Trial Profile

Open-Label, Multicenter, Phase 1 Study to Assess the Safety of P-BCMA-ALLO1 in Subjects With Relapsed / Refractory Multiple Myeloma (MM)

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 19 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

09 Dec 2024 According to Poseida Therapeutics media release, data from this study presented at the 66th ASH Annual Meeting and Exposition being held in San Diego on December 7-10, 2024.
09 Dec 2024 Results published in the Poseida Therapeutics Media Release.
14 Nov 2024 According to Poseida Therapeutics media release, data company ill provide an overview of recently reported interim Phase 1 results from this study at virtual R&D Day to be held today at 10:00am ET / 7:00am PT.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com